^
    Back
    Association details:
    Biomarker:Chr t(14;16)
    Cancer:Multiple Myeloma
    Regimen: (bortezomib + Darzalex (daratumumab) + dexamethasone injection)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    J Hematol Oncol
    Title:

    Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

    Published date:
    08/20/2020
    Excerpt:
    High-risk patients had t(4;14), t(14;16), and/or del17p abnormalities....Among a subset of patients who had received 1 prior line of therapy, treatment with D-Vd prolonged median PFS versus Vd in patients with standard cytogenetic risk (29.8 months vs 7.5 months; HR, 0.25; 95% CI, 0.15–0.42; P < 0.0001; Fig. 1c) and high cytogenetic risk (20.1 months vs 8.4 months; HR, 0.20; 95% CI, 0.06–0.62; P = 0.0026...
    DOI:
    10.1186/s13045-020-00948-5
    Trial ID:
    CASTOR